Communiqués Addex Therapeutics Ltd

Actions

ADXN

CH0029850754

Recherche biotechnologique et médicale

Temps Différé Swiss Exchange 14:28:10 03/09/2026			Varia. 5j.	Varia. 1 janv.
0,0260 ^CHF	-3,70 %		-9,72 %	-53,07 %

26/08	Addex Therapeutics lève 3 millions de dollars via une offre d'American Depositary Shares	MT
26/08	Addex lève 2,8 millions de dollars via un accord avec H.C. Wainwright	AW

Communiqués

26/08	ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027	GL
08/07	Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness	GL
30/06	Addex Therapeutics : Results ( 434)	PU
30/06	Addex Shareholders Approve All Resolutions at Annual General Meeting	GL
26/06	Addex Therapeutics : Quarter 1 Report ( 433)	PU
25/06	Addex Therapeutics : Quarter 1 Report (561782364078Addex Therapeutics Q1 2026 financial statements)	PU
25/06	Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	GL
22/06	Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026	GL
08/06	Addex Convenes Annual General Meeting 2026	AQ
05/06	Addex Therapeutics : Invitation ( 432)	PU
05/06	Addex Convenes Annual General Meeting 2026	GL
30/04	Addex Therapeutics : Annual Report ( 431)	PU
30/04	Addex Reports Full Year 2025 Financial Results and Provides Corporate Update	GL
30/04	Addex Reports Full Year 2025 Financial Results and Provides Corporate Update	AQ
29/04	Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model	GL
23/04	Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026	GL
21/04	Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model	GL
21/04	Addex Therapeutics : GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model	PU
03/02	Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment	GL
03/02	Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment	AQ
07/01	Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia	GL
11/12	Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.	GL
04/12	Addex Therapeutics : Quarter 3 Report ( 428)	PU
04/12	Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update	GL
04/12	Addex Therapeutics : Reports 2025 Third Quarter Financial Results and Provides Corporate Update	PU